• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.

作者信息

Kim Insook, Seo Shirley

机构信息

Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

Clin Pharmacol Ther. 2021 Feb;109(2):292-294. doi: 10.1002/cpt.1978. Epub 2020 Aug 2.

DOI:10.1002/cpt.1978
PMID:32740920
Abstract
摘要

相似文献

1
Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.利用临床药理学优化非酒精性脂肪性肝炎和胆汁淤积性肝病的药物研发：研讨会报告
Clin Pharmacol Ther. 2021 Feb;109(2):292-294. doi: 10.1002/cpt.1978. Epub 2020 Aug 2.
2
Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.靶向CCR2/5治疗非酒精性脂肪性肝炎（NASH）和肝纤维化：机遇与挑战
Expert Opin Investig Drugs. 2020 Feb;29(2):89-92. doi: 10.1080/13543784.2020.1718106. Epub 2020 Jan 20.
3
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.非酒精性脂肪性肝炎（NASH）和肝纤维化：新兴疗法。
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:649-662. doi: 10.1146/annurev-pharmtox-010617-052545. Epub 2017 Oct 20.
4
How effective are nonalcoholic fatty liver disease models for drug discovery?非酒精性脂肪性肝病模型在药物发现中的有效性如何？
Expert Opin Drug Discov. 2020 Nov;15(11):1237-1240. doi: 10.1080/17460441.2020.1776258. Epub 2020 Jun 11.
5
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.西妥昔单抗对非酒精性脂肪性肝炎引起的桥接纤维化或代偿性肝硬化患者无效。
Gastroenterology. 2018 Oct;155(4):1140-1153. doi: 10.1053/j.gastro.2018.07.006. Epub 2018 Jul 7.
6
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.专家小组审查，以比较美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）关于非酒精性脂肪性肝炎药物开发及终点指标的指南
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
7
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
8
New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.新型和新兴的抗纤维化治疗药物在慢性肝脏疾病中进入或已经进入临床试验。
Curr Opin Pharmacol. 2019 Dec;49:60-70. doi: 10.1016/j.coph.2019.09.006. Epub 2019 Oct 5.
9
Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.靶向细胞死亡与无菌性炎症循环以治疗非酒精性脂肪性肝炎
Semin Liver Dis. 2016 Feb;36(1):27-36. doi: 10.1055/s-0035-1571272. Epub 2016 Feb 12.
10
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.非酒精性脂肪性肝病的药物研发：研究中的挑战、监管途径及研究终点
Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22.